Pharmacologic treatments for covid-19 patients
Proxalutamide vs Standard care/Placebo
This comparison will not be updated. Last search date 28 Feb, 2022.
Study McCoy J, Frontiers (2021) has been retracted on June 10, 2022. The study was excluded from the analysis and grade assessment by August 10 the latest.
Hospitalized patients
Forest plots
(last update: 2021-07-08)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=214
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04728802 Cadegiani F, medRxiv, 2021 Full text Commentary Commentary |
Private |
Proxalutamide |
Placebo |
RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 8 centers in Brazil. | N=645 |
Low Details |
|